% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • th3k33p3r24 th3k33p3r24 Aug 14, 2013 11:48 AM Flag

    Can someone explain this to me?

    I don't understand why we are still languishing in the mid-6's after these results. I would think that we would justify at least $400M market cap just on the Ampion results alone - closer to $10. Are there just some holders from the 3's and 4's taking profits and selling early? Are the shorts just not covering? Is it just that the tree fell and no one was there to hear it because we have so little coverage? A combination of all? Will it just take a day or two to get through these things, attract some more attention, and get to what I consider to be reasonable levels? Am I just too impatient?

    PS - Ampiooooh need not reply.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hang in there and be patient. Today's results just removed all the risk from being long.

      You are exactly correct that "nobody heard the tree fall" because Ampio does not have a major banker but that is about to change soon.

      If they had a major banker shares would easily be over $20 on trial results this powerful. EASILY!!!!

      This will be very entertaining and enjoyable to hear all the negative #$%$ from ampiooooooooooooooooooh and other idiots who don't have a clue about what they are talking about.

      Let the fun games begin.

      Just hang on for the ride and smile.

      This one will make the patient investors a fortune and will cost the shorts dearly.

      Just try to imagine what Ampion alone is worth in a $65 billion anti-inflammatory market where EVERY one has terrible adverse side effects EXCEPT AMPION which will obviously be commercial for may indications.

      And just imagine what the numbers imply.

      It is far greater than the most optimistic forecast.

      And remember, this does not even include, Zertane, Zertane ED, Optina, Vasaloc, ORP and NCE001.

      Enjoy a long, long ride for several years to come!!!!!!

      Sentiment: Strong Buy

    • There may be any number of reasons for lack of response. It may be useful to recall the fair-value estimates in the Aegis Nov 2012 report. As the stock receives more coverage, perhaps that will help.

      "Based on a comparables analysis, it appears the stock is worth $11.00 per share, utilizing our estimate of a roughly $500 million risk-adjusted net present value (rNPV) for the firm’s products...this assumes 49 million shares outstanding (fully-diluted)."

      Product, Launch-year, Peak Sales, NPV/share
      Ampion 2015 $2.2B $6.11
      Zertane 2014 $680MM $1.30
      Optina 2015 $580MM $1.00

      Other major investors probably are working from similar numbers.

      Sentiment: Strong Buy

    • It has to be shorts manipulating stock to make sure those 360 August puts don't expire worthless!

      Why cover? Today's press release was typical of AMPE just telling half the story.

      Oh no, maybe that Zertane deal is tomorrow!!!!!!!

    • Almost always, there's a dip before it skyrockets. Be patient.

      Sentiment: Strong Buy

      • 1 Reply to dkotanto
      • There's been so many dreams on this board about fantasy valuations anything less than expectations is going to be a big disappointment. They still have to deliver on the Zertane partnership and optina so we're in for more waiting. I thought we'd here about this late in the second week of august, so I had a lucky guess. no idea when we'll hear about the rest of the trials GLTA. Anybody think the rest of the news will show up before the end of August

        Sentiment: Hold

    • This was great news, and the stock should now trend higher over the coming months as they have more announcements about starting the final Phase 3 trial, publish more data, and announce what I expect would be some kind of partnership regarding Ampion. You can say goodbye to Synvisc, as Ampion is the future standard of treatment.

0.7589-0.0344(-4.34%)3:28 PMEDT